PMID- 31248389
OWN - NLM
STAT- MEDLINE
DCOM- 20191231
LR  - 20200225
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jun 27
TI  - Prevalence of human herpesviruses in biliary fluid and their association with 
      biliary complications after liver transplantation.
PG  - 110
LID - 10.1186/s12876-019-1033-x [doi]
LID - 110
AB  - BACKGROUND: Beta-herpesviruses are common opportunistic pathogens that cause 
      morbidity after liver transplantation (LT). METHODS: Objective of the study was 
      to evaluate the prevalence and correlation of herpesviruses in bile, blood and 
      liver tissue and to investigate their association with biliary complications and 
      retransplantation (re-LT) free survival after LT. The study design is a 
      single-center case-control study. We performed quantative polymerase chain 
      reaction (qPCR) for herpesvirus 1-8 DNA in bile, blood and liver tissue of 73 
      patients after first LT and analyzed their clinical courses retrospectively. 
      RESULTS: The median follow-up was 48 months (range 2-102), during which a total 
      of 16 patients underwent re-LT and 11 patients died. Of the patients, 46.5% 
      received valganciclovir prophylaxis at the time of bile sample acquisition. 
      Cytomegalovirus (CMV) (18.3%), human herpesvirus 6 (HHV-6) (34.2%), human 
      herpesvirus 7 (HHV-7) (20.5%) and Epstein-Barr virus (EBV) (16.4%) were highly 
      prevalent in bile after LT, while herpes simpex virus 1 and 2 (HSV-1, HSV-2), 
      varicella-zoster virus (VZV) and human herpesvirus 8 (HHV-8) were not or rarely 
      detected in bile. Valganciclovir prophylaxis did not reduce the prevalence of 
      HHV-6 and HHV-7 in bile, but it did reduce the presence of CMV and EBV. The 
      presence of HHV-6 in bile was associated with non-anastomotic biliary strictures 
      (NAS) and acute cellular rejection (ACR). CONCLUSIONS: CMV, EBV, HHV-6 and HHV-7 
      are more prevalent in biliary fluid than in liver biopsy or blood serum after LT. 
      HHV-6 and HHV-7 might be associated with biliary complications after LT. Biliary 
      fluids might be an attractive target for routine herpesvirus detection.
FAU - Rauber, Conrad
AU  - Rauber C
AUID- ORCID: 0000-0002-2156-8426
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany. conrad.rauber@gmx.de.
AD  - INSERM U1015, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. 
      conrad.rauber@gmx.de.
FAU - Bartelheimer, Katja
AU  - Bartelheimer K
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Zhou, Taotao
AU  - Zhou T
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Rupp, Christian
AU  - Rupp C
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Schnitzler, Paul
AU  - Schnitzler P
AD  - Department of Virology, University Hospital Heidelberg, Heidelberg, Germany.
FAU - Schemmer, Peter
AU  - Schemmer P
AD  - Department of General, Visceral and Transplant Surgery, University Hospital 
      Heidelberg, Heidelberg, Germany.
AD  - Department of Surgery, Division of Transplant Surgery, Medical University of 
      Graz, Graz, Austria.
FAU - Sauer, Peter
AU  - Sauer P
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Weiss, Karl Heinz
AU  - Weiss KH
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Gotthardt, Daniel Nils
AU  - Gotthardt DN
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20190627
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - GCU97FKN3R (Valganciclovir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/therapeutic use
MH  - Bile/*virology
MH  - Blood/virology
MH  - Case-Control Studies
MH  - Cytomegalovirus/isolation & purification
MH  - DNA, Viral/blood/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Herpesviridae/*isolation & purification
MH  - Herpesviridae Infections/complications/*epidemiology/prevention & control
MH  - Humans
MH  - Liver/virology
MH  - Liver Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Postoperative Complications/*virology
MH  - Prevalence
MH  - Reoperation
MH  - Valganciclovir/therapeutic use
PMC - PMC6598275
OTO - NOTNLM
OT  - Bile
OT  - Complication
OT  - HHV-6
OT  - Herpesvirus
OT  - Liver transplantation
OT  - Non-anastomotic stricture
OT  - Stricture
COIS- All authors declare that they have no competing interests.
EDAT- 2019/06/30 06:00
MHDA- 2020/01/01 06:00
PMCR- 2019/06/27
CRDT- 2019/06/29 06:00
PHST- 2018/10/22 00:00 [received]
PHST- 2019/06/21 00:00 [accepted]
PHST- 2019/06/29 06:00 [entrez]
PHST- 2019/06/30 06:00 [pubmed]
PHST- 2020/01/01 06:00 [medline]
PHST- 2019/06/27 00:00 [pmc-release]
AID - 10.1186/s12876-019-1033-x [pii]
AID - 1033 [pii]
AID - 10.1186/s12876-019-1033-x [doi]
PST - epublish
SO  - BMC Gastroenterol. 2019 Jun 27;19(1):110. doi: 10.1186/s12876-019-1033-x.